INPART - a psycho-oncological intervention for partners of patients with haemato-oncological disease - study protocol.


Journal

BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800

Informations de publication

Date de publication:
05 Sep 2019
Historique:
received: 31 03 2019
accepted: 26 08 2019
entrez: 7 9 2019
pubmed: 7 9 2019
medline: 27 2 2020
Statut: epublish

Résumé

Suffering from cancer confronts both the patient and their partner with a number of psychosocial challenges in various aspects of their life. These challenges may differentially impact on quality of life, coping ability and compliance to treatment. This especially holds true for haemato-oncological diseases. To date, psychological interventions have predominantly been developed for oncological patients however specific interventions for partners of haemato-oncological patients are rare. In this study we aim to conduct a psycho-oncological group-intervention for partners of patients with haemato-oncological diseases. The aim of the intervention is to significantly reduce symptoms of depression and anxiety in the partners and the patient, as well as enhancing dyadic coping. The design of the INPART-study is an unblinded, randomised controlled trial with 2 treatment conditions (experimental and control) and assessments at baseline, 3 and 6 months. It will be conducted at three study centres: the university medical centre's in Leipzig, Hannover and Ulm. The outcome criteria will be a reduction in depressive and anxiety symptoms as well as an improvement of dyadic coping. This trial shall provide information regarding the efficiency of a psycho-oncological intervention for partners of patients with haemato-oncological diseases and give references to the possible outcome in terms of dyadic coping and the reduction of mental strain. The study was supported by a grant from the German José Carreras Leukaemia Foundation. ISRCTN16085028 ; 20/03/2019.

Sections du résumé

BACKGROUND BACKGROUND
Suffering from cancer confronts both the patient and their partner with a number of psychosocial challenges in various aspects of their life. These challenges may differentially impact on quality of life, coping ability and compliance to treatment. This especially holds true for haemato-oncological diseases. To date, psychological interventions have predominantly been developed for oncological patients however specific interventions for partners of haemato-oncological patients are rare. In this study we aim to conduct a psycho-oncological group-intervention for partners of patients with haemato-oncological diseases. The aim of the intervention is to significantly reduce symptoms of depression and anxiety in the partners and the patient, as well as enhancing dyadic coping.
METHODS METHODS
The design of the INPART-study is an unblinded, randomised controlled trial with 2 treatment conditions (experimental and control) and assessments at baseline, 3 and 6 months. It will be conducted at three study centres: the university medical centre's in Leipzig, Hannover and Ulm. The outcome criteria will be a reduction in depressive and anxiety symptoms as well as an improvement of dyadic coping.
DISCUSSION CONCLUSIONS
This trial shall provide information regarding the efficiency of a psycho-oncological intervention for partners of patients with haemato-oncological diseases and give references to the possible outcome in terms of dyadic coping and the reduction of mental strain. The study was supported by a grant from the German José Carreras Leukaemia Foundation.
TRIAL REGISTRATION BACKGROUND
ISRCTN16085028 ; 20/03/2019.

Identifiants

pubmed: 31488083
doi: 10.1186/s12885-019-6094-2
pii: 10.1186/s12885-019-6094-2
pmc: PMC6729088
doi:

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

885

Subventions

Organisme : José Carreras Leukämie-Stiftung
ID : DJCLS 23R/2016
Organisme : José Carreras Leukämie-Stiftung
ID : DJCLS 23R/2016

Références

Ann Behav Med. 1999 Spring;21(2):111-21
pubmed: 10499131
JAMA. 1999 Nov 10;282(18):1737-44
pubmed: 10568646
Eur J Cancer. 2003 Jul;39(11):1517-24
pubmed: 12855257
J Affect Disord. 2004 Jul;81(1):61-6
pubmed: 15183601
Health Psychol. 2005 Nov;24(6):635-41
pubmed: 16287411
Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
J Clin Oncol. 2007 Apr 10;25(11):1403-11
pubmed: 17416860
Psychol Bull. 2008 Jan;134(1):1-30
pubmed: 18193993
Med Care. 2008 Mar;46(3):266-74
pubmed: 18388841
Psychooncology. 2009 May;18(5):490-9
pubmed: 18821528
Psychother Psychosom. 2010;79(3):136-48
pubmed: 20185970
Ann Behav Med. 2010 Oct;40(2):218-27
pubmed: 20652462
Psychooncology. 2013 Feb;22(2):299-307
pubmed: 22081505
CMAJ. 2012 Feb 21;184(3):E191-6
pubmed: 22184363
J Clin Oncol. 2012 Feb 10;30(5):539-47
pubmed: 22253460
Psychooncology. 2013 Mar;22(3):555-63
pubmed: 22290823
Psychother Psychosom Med Psychol. 2012 May;62(5):185-94
pubmed: 22565336
Support Care Cancer. 2013 Jan;21(1):75-85
pubmed: 22661096
Lancet Oncol. 2013 Jul;14(8):721-32
pubmed: 23759376
BMJ Support Palliat Care. 2012 Sep;2(3):224-30
pubmed: 24654195
J Cancer Surviv. 2014 Sep;8(3):472-84
pubmed: 24752701
Cancer. 2015 May 1;121(9):1513-9
pubmed: 25677095
Nervenarzt. 2015 Mar;86(3):266, 268-70, 272-3
pubmed: 25694250
Leuk Lymphoma. 2017 Mar;58(3):655-665
pubmed: 27333121
Med Care. 1996 Mar;34(3):220-33
pubmed: 8628042

Auteurs

Inga Lorenz (I)

Department of Psychosomatic Medicine and Psychotherapy, University Medical Center Ulm, Albert-Einstein-Allee 23, 89081, Ulm, Germany.

Daniela Bodschwinna (D)

Department of Psychosomatic Medicine and Psychotherapy, University Medical Center Ulm, Albert-Einstein-Allee 23, 89081, Ulm, Germany.
Comprehensive Cancer Center Ulm, Ulm, Germany.

Nina Hallensleben (N)

Department of Medical Psychology and Medical Sociology, University Medical Center Leipzig, Leipzig, Germany.

Hartmut Döhner (H)

Comprehensive Cancer Center Ulm, Ulm, Germany.
Department of Internal Medicine III, University Medical Center Ulm, Ulm, Germany.

Dietger Niederwieser (D)

Department of Haematology and Oncology, University Medical Center Leipzig, Leipzig, Germany.

Tanja Zimmermann (T)

Department of Psychosomatic Medicine and Psychotherapy, Hannover University Medical School, Hannover, Germany.

Anja Mehnert (A)

Department of Medical Psychology and Medical Sociology, University Medical Center Leipzig, Leipzig, Germany.

Harald Gündel (H)

Department of Psychosomatic Medicine and Psychotherapy, University Medical Center Ulm, Albert-Einstein-Allee 23, 89081, Ulm, Germany.
Comprehensive Cancer Center Ulm, Ulm, Germany.

Jochen Ernst (J)

Department of Medical Psychology and Medical Sociology, University Medical Center Leipzig, Leipzig, Germany.

Klaus Hoenig (K)

Department of Psychosomatic Medicine and Psychotherapy, University Medical Center Ulm, Albert-Einstein-Allee 23, 89081, Ulm, Germany. klaus.hoenig@uniklinik-ulm.de.
Comprehensive Cancer Center Ulm, Ulm, Germany. klaus.hoenig@uniklinik-ulm.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH